compounds sitagliptin Search Results


compounds sitagliptin  (MedChemExpress)
93
MedChemExpress compounds sitagliptin
IC 50 plots of <t>Sitagliptin</t> (A) and Linagliptin (C) in MIA PaCa-2 and PANC-1 cells and 2D structures Sitagliptin (B) and Linagliptin (D) were depicted. The viability percentage was normalized to the control. All the experiments were performed in double triplicates ( n = 6) and the data were shown as mean ± SD respectively
Compounds Sitagliptin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/compounds sitagliptin/product/MedChemExpress
Average 93 stars, based on 1 article reviews
compounds sitagliptin - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
sitagliptin  (Boehringer Ingelheim)
90
Boehringer Ingelheim sitagliptin
IC 50 plots of <t>Sitagliptin</t> (A) and Linagliptin (C) in MIA PaCa-2 and PANC-1 cells and 2D structures Sitagliptin (B) and Linagliptin (D) were depicted. The viability percentage was normalized to the control. All the experiments were performed in double triplicates ( n = 6) and the data were shown as mean ± SD respectively
Sitagliptin, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sitagliptin/product/Boehringer Ingelheim
Average 90 stars, based on 1 article reviews
sitagliptin - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
auda  (Cayman Chemical)
90
Cayman Chemical auda
IC 50 plots of <t>Sitagliptin</t> (A) and Linagliptin (C) in MIA PaCa-2 and PANC-1 cells and 2D structures Sitagliptin (B) and Linagliptin (D) were depicted. The viability percentage was normalized to the control. All the experiments were performed in double triplicates ( n = 6) and the data were shown as mean ± SD respectively
Auda, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/auda/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
auda - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
vildagliptin  (Novartis)
90
Novartis vildagliptin
IC 50 plots of <t>Sitagliptin</t> (A) and Linagliptin (C) in MIA PaCa-2 and PANC-1 cells and 2D structures Sitagliptin (B) and Linagliptin (D) were depicted. The viability percentage was normalized to the control. All the experiments were performed in double triplicates ( n = 6) and the data were shown as mean ± SD respectively
Vildagliptin, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vildagliptin/product/Novartis
Average 90 stars, based on 1 article reviews
vildagliptin - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
sitagliptin related compound 1  (BOC Sciences)
N/A
Sitagliptin Related Compound 1 is an impurity of Sitagliptin Sitagliptin is a dipeptidyl peptidase 4 DPP 4 inhibitor for treatment of diabetes mellitus type 2
   Buy from Supplier
sitagliptin related compound  (TLC Pharmaceutical Standards)
N/A
Sitagliptin Related Compound
   Buy from Supplier
sitagliptin  (MedChemExpress)
N/A
Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
   Buy from Supplier
sitagliptin-d4  (MedChemExpress)
N/A
Sitagliptin-d4 (phosphate) is the deuterium labeled Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
   Buy from Supplier
sitagliptin in acetonitrile  (Dr Ehrenstorfer)
N/A
Sitagliptin 100 µg mL in Acetonitrile
   Buy from Supplier
sitagliptin ep impurity a  (Enamine Ltd)
N/A
(S)-Sitagliptin is the S-isomer of Sitagliptin Phosphate, as an impurity.
   Buy from Supplier
sitagliptin  (Enamine Ltd)
N/A
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used for the management of type 2 diabetes mellitus.
   Buy from Supplier

Image Search Results


IC 50 plots of Sitagliptin (A) and Linagliptin (C) in MIA PaCa-2 and PANC-1 cells and 2D structures Sitagliptin (B) and Linagliptin (D) were depicted. The viability percentage was normalized to the control. All the experiments were performed in double triplicates ( n = 6) and the data were shown as mean ± SD respectively

Journal: BMC Pharmacology & Toxicology

Article Title: Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma

doi: 10.1186/s40360-025-01020-z

Figure Lengend Snippet: IC 50 plots of Sitagliptin (A) and Linagliptin (C) in MIA PaCa-2 and PANC-1 cells and 2D structures Sitagliptin (B) and Linagliptin (D) were depicted. The viability percentage was normalized to the control. All the experiments were performed in double triplicates ( n = 6) and the data were shown as mean ± SD respectively

Article Snippet: The compounds Sitagliptin and Linagliptin were purchased from MedChemExpress.

Techniques: Control

Wound healing of Sitagliptin and Linagliptin in MIA PaCa-2 (A & C) and PANC-1 (B & D) cells. The wound closure was measured at 0, 24, and 48 h. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Journal: BMC Pharmacology & Toxicology

Article Title: Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma

doi: 10.1186/s40360-025-01020-z

Figure Lengend Snippet: Wound healing of Sitagliptin and Linagliptin in MIA PaCa-2 (A & C) and PANC-1 (B & D) cells. The wound closure was measured at 0, 24, and 48 h. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Article Snippet: The compounds Sitagliptin and Linagliptin were purchased from MedChemExpress.

Techniques:

Colony formation of Sitagliptin and Linagliptin in MIA PaCa-2 (A) and PANC-1 (B) cells. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Journal: BMC Pharmacology & Toxicology

Article Title: Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma

doi: 10.1186/s40360-025-01020-z

Figure Lengend Snippet: Colony formation of Sitagliptin and Linagliptin in MIA PaCa-2 (A) and PANC-1 (B) cells. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Article Snippet: The compounds Sitagliptin and Linagliptin were purchased from MedChemExpress.

Techniques:

Intracellular ROS production (DCFH-DA) and DNA fragmentation (DAPI) of Sitagliptin and Linagliptin in MIA PaCa-2 (A & B) and PANC-1 (C & D) cells respectively. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Journal: BMC Pharmacology & Toxicology

Article Title: Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma

doi: 10.1186/s40360-025-01020-z

Figure Lengend Snippet: Intracellular ROS production (DCFH-DA) and DNA fragmentation (DAPI) of Sitagliptin and Linagliptin in MIA PaCa-2 (A & B) and PANC-1 (C & D) cells respectively. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Article Snippet: The compounds Sitagliptin and Linagliptin were purchased from MedChemExpress.

Techniques:

Apoptosis induction potential of Sitagliptin and Linagliptin in MIA PaCa-2 (A) and PANC-1 cells (B) . The apoptosis induced cells in the control and treated groups were determined by employing FITC detection in x-axis and PI detection in y-axis respectively. In the plot, LL, LR, UR, & UL represents the amount of cells in the normal, early apoptotic, late apoptotic, and necrosis states respectively. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Journal: BMC Pharmacology & Toxicology

Article Title: Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma

doi: 10.1186/s40360-025-01020-z

Figure Lengend Snippet: Apoptosis induction potential of Sitagliptin and Linagliptin in MIA PaCa-2 (A) and PANC-1 cells (B) . The apoptosis induced cells in the control and treated groups were determined by employing FITC detection in x-axis and PI detection in y-axis respectively. In the plot, LL, LR, UR, & UL represents the amount of cells in the normal, early apoptotic, late apoptotic, and necrosis states respectively. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Article Snippet: The compounds Sitagliptin and Linagliptin were purchased from MedChemExpress.

Techniques: Control

mRNA expression analysis of Sitagliptin and Linagliptin in MIA PaCa-2 (A) and PANC-1 cells (B) . All the mRNA expression levels were normalized with GAPDH, and the normalized expression levels of BAX, BCL-2, CASP3, PARP, KRAS, BRAF, MEK, and ERK were calculated by 2-ΔΔCT method. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Journal: BMC Pharmacology & Toxicology

Article Title: Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma

doi: 10.1186/s40360-025-01020-z

Figure Lengend Snippet: mRNA expression analysis of Sitagliptin and Linagliptin in MIA PaCa-2 (A) and PANC-1 cells (B) . All the mRNA expression levels were normalized with GAPDH, and the normalized expression levels of BAX, BCL-2, CASP3, PARP, KRAS, BRAF, MEK, and ERK were calculated by 2-ΔΔCT method. All the experiments were performed in triplicates ( n = 3) and the data were shown as mean ± SD respectively

Article Snippet: The compounds Sitagliptin and Linagliptin were purchased from MedChemExpress.

Techniques: Expressing

Commonly shared targets of pancreatic ductal adenocarcinoma (PDAC) with Sitagliptin (A1) and Linagliptin (A2) were showed in Venn diagram. The protein-protein interaction (PPI) network of 63 commonly shared targets of Sitagliptin (B1) and 75 commonly shared targets of Linagliptin (B2) were showed. Then the hub genes were identified by using parametes like MCC, degree, betweenness, & closeness for Sitagliptin (C1) and Linagliptin (C2) and showed in Venn diagram. The PPI interaction network of TOP hub genes were shown, for Sitagliptin (D1) and Linagliptin (D2) respectively

Journal: BMC Pharmacology & Toxicology

Article Title: Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma

doi: 10.1186/s40360-025-01020-z

Figure Lengend Snippet: Commonly shared targets of pancreatic ductal adenocarcinoma (PDAC) with Sitagliptin (A1) and Linagliptin (A2) were showed in Venn diagram. The protein-protein interaction (PPI) network of 63 commonly shared targets of Sitagliptin (B1) and 75 commonly shared targets of Linagliptin (B2) were showed. Then the hub genes were identified by using parametes like MCC, degree, betweenness, & closeness for Sitagliptin (C1) and Linagliptin (C2) and showed in Venn diagram. The PPI interaction network of TOP hub genes were shown, for Sitagliptin (D1) and Linagliptin (D2) respectively

Article Snippet: The compounds Sitagliptin and Linagliptin were purchased from MedChemExpress.

Techniques: